FRONTEO : Acquisition of patent grant in Europe for “Conversational Dementia Diagnosis Support AI Program”

　FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter referred to as FRONTEO) is pleased to announce that it has received a patent allowance notification for the "Conversational Dementia Diagnosis Support AI Program" from the European Patent Office. .

　The "Conversational Dementia Diagnosis Support AI Program" uses FRONTEO's natural language analysis AI engine "KIBIT" to detect the presence or absence of cognitive decline from a natural conversation of about 5 to 10 minutes between a medical practitioner and a patient. It's a screening program. As the global population ages and medical costs related to dementia increase year by year, we are promoting research and development with the aim of improving prognosis through early detection of dementia, reducing the burden of diagnosing dementia, and using it as a new digital biomarker. I'm here.

　FRONTEO has registered patent rights for this program in Japan in July 2020 and in South Korea in August 2021, and has exclusive development and sales in the United States, Europe, China, and South Korea with Keio University. We have a contract1 ⁾ . We believe that the acquisition of a patent grant in Europe is an important step in expanding this program to overseas markets. This patent is scheduled to be registered in Germany, France, Italy, the United Kingdom, and Spain.

　The International Alzheimer's Association reports that the number of people with Alzheimer's disease in the world almost doubles every 20 years, from 58.66 million in 2020 to 82.05 million in 2030 and 114.83 million in 2040. It is estimated that the number of people with dementia will reach approximately 152.24 million by 2050 ²⁾ , and countermeasures against dementia are an important issue not only in Japan but also worldwide. FRONTEO will continue to contribute to solving medical and social issues associated with aging and improving the QOL of the elderly through research and development and commercialization of AI technology.

　The impact of this matter alone on the Company's business performance will be minor.

1) FRONTEO: Concluded a global license agreement with Keio University for the "Conversational Dementia Diagnosis Support AI Program", https://www.fronteo.com/20210629 2) Alzheimer's Disease International :
Numbers of people with dementia worldwide, https ://www.alzint.org/resource/numbers-of-people-with-dementia-worldwide/ [Confirmed August 8, 2023]

■ About FRONTEO　URL: https://www.fronteo.com/
FRONTEO is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT". Based on the philosophy of "providing solutions that do not overlook risks and opportunities buried in records and realizing fairness in the information society," extract meaningful and important information from vast amounts of text data and complex networks. Our strengths are natural language processing and network analysis technologies that support advanced judgments by experts. We are developing businesses in the areas of legal tech AI, business intelligence, life science AI, and economic security, and contributing to solving various corporate and social issues. Founded in August 2003, listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth) on June 26, 2007. The company operates in Japan, the United States, South Korea, and Taiwan. Acquisition of first-class medical device manufacturing and sales business license, notification of controlled medical device sales business. Capital 3,042,317,000 yen (as of March 31, 2023).

* FRONTEO and KIBIT are registered trademarks of FRONTEO in Japan.